Navigation Links
Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
Date:7/9/2009

MARSEILLE, France, July 10 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext: ALIPS) today reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer indicated for the first time that the Genomic Grade could be considered as an adjunct to the histological grade. These new guidelines, published online in Annals of Oncology, represent the consensus opinion of 43 European and US experts on early breast cancer treatment that emerged from the conference which took place in March 2009.

According to the guidelines, histological grade 2 is considered as "not useful for chemo-endocrine-therapy decision" as compared to the established decision making value of histological grades 1 or 3. The panel also stated that the dominant prognostic information is provided by proliferation.

MapQuantTM Genomic Grade is available to European oncologists and pathologists. The genomic grade test analyzes a set of 97 genes to precisely quantify the proliferation potential of the tumor, and has been validated in several studies, covering more than 2 800 tumor samples. MapQuantTM Genomic Grade contributes to high-quality phenotyping of breast cancer, by resolving 80% of histological grade 2 tumors in genomic grade 1 or 3 of similar long term outcome as histological grades 1 and 3.

"The St Gallen Consensus Panel decision to identify the genomic grade as a valuable adjunct in the pathological characterisation of breast cancer legitimates Ipsogen strategy to provide pathologists and oncologists with state of the art molecular tests generating critical information for treatment decisions" said Helene Peyro-Saint-Paul, Chief Medical Officer, Ipsogen. "These new recommendations are going to support our regulatory and reimbursement efforts, a critical step to make our assay widely available to patients and pathologists/physicians," added Vincent Fert, Chief Executive Officer, Ipsogen
'/>"/>

SOURCE Ipsogen SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
2. Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
3. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
4. BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
5. PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
6. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
8. Spherix Reports First Quarter 2009 Earnings
9. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
10. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
11. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... Executive Officer of the company, effective December 22, 2014. ... "The Board of Directors of ConvaTec thanks Mr. Berger ... three years," said Magnus Lundberg , the Chairman ... the company is well positioned for the future."  The ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) today ... has been filed and is now open and that ... Department of Health and Human Services (HHS), through the ... "We are extremely pleased to have the IND now ... a significant milestone in our company,s partnership with BARDA ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... today announced the appointment of Wendy Dixon , ... 30 years of pharmaceutical development and commercial experience to ... product launches and portfolio evaluation in cardiometabolic and primary ...
... , MADRID , April 21 PharmaMar, ... with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association ... from April 17-21 . , ... The AACR meeting is the leading convention on cancer research, ...
Cached Medicine Technology:Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors 2Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors 3PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention 2PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention 3
(Date:12/25/2014)... When head lice hits a home or school, ... get rid of it while keeping it from taking over ... have the solution right in their neighborhood: Lice Troopers ... provides full spectrum head lice screening and treatment services to ... Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Each year ... and 2 million hospital admissions across the nation (according ... ). The CDC’s National Hospital Ambulatory Medical Care ... a survey conducted in 2010. They estimated that there ... that resulted in a primary diagnosis of broken bone ...
(Date:12/24/2014)... 25, 2014 Epigenetics finds applications in ... including oncology, drug discovery, developmental biology, and research for ... one of the most widely used techniques for the ... the prevalence of cancer is rapidly growing worldwide. In ... million cancer deaths, and 32.6 million people living with ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3
... 12 million people in the United States are cancer survivors. ... annually than the care of people who have never had ... are treated for and survive cancer are susceptible to later ... per year. People are considered cancer survivors from the moment ...
... Multiple Sclerosis sufferers emotional support through group therapy sessions ... NHS almost 500 per patient, a study at The ... planning a larger multi-centre study into the issue to ... MS services currently provided by the NHS. The ...
... identify patients who will benefit from a potentially toxic second ... of cure in select patients with head and neck cancer. ... of the American Cancer Society, the findings could help guide ... Radiation is often used to treat patients with head and ...
... the brain activity of teens, recorded while they are listening ... songs. "We have scientifically demonstrated that you can, to ... predict cultural popularity," says Gregory Berns, a neuroeconomist and director ... Consumer Psychology is publishing the results of the study, ...
... June 10 (HealthDay News) -- The debate over whether or not ... study finds a small risk among people who are heavy cell ... Dr. Otis Brawley, chief medical officer of the American Cancer ... "the study is not conclusive that cell phones cause brain tumors." ...
... , SATURDAY, June 11 (HealthDay News) -- Baseline concussion ... some cases, an expert warns. Baseline concussion testing provides ... reaction time, working memory and attention span. Athletes who suffer ... large decrease in the score, they are typically banned from ...
Cached Medicine News:Health News:Cancer survivors spend more on health care 2Health News:Group therapy helps MS sufferers cope with depression, study finds 2Health News:Group therapy helps MS sufferers cope with depression, study finds 3Health News:Certain head and neck cancer patients benefit from second round of treatment 2Health News:Teen brain data may predict pop song success, Emory study finds 2Health News:Teen brain data may predict pop song success, Emory study finds 3Health News:Heavy Cell Phone Use Might Raise Risk of Brain Tumors 2Health News:Heavy Cell Phone Use Might Raise Risk of Brain Tumors 3Health News:Validity of Baseline Concussion Tests Questioned 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: